7-124841179-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_015450.3(POT1):c.1164-1G>A variant causes a splice acceptor, intron change. The variant allele was found at a frequency of 0.0000398 in 1,609,146 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000042 ( 0 hom. )
Consequence
POT1
NM_015450.3 splice_acceptor, intron
NM_015450.3 splice_acceptor, intron
Scores
4
2
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 5.12
Genes affected
POT1 (HGNC:17284): (protection of telomeres 1) This gene is a member of the telombin family and encodes a nuclear protein involved in telomere maintenance. Specifically, this protein functions as a member of a multi-protein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation. Increased transcriptional expression of this gene is associated with stomach carcinogenesis and its progression. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, LoF is a know mechanism of disease, Cryptic splice site detected, with MaxEntScore 7.6, offset of 43, new splice context is: atttggatataatttttcAGgat. Cryptic site results in frameshift change. If cryptic site found is not functional and variant results in exon loss, it results in frameshift change.
PP5
Variant 7-124841179-C-T is Pathogenic according to our data. Variant chr7-124841179-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 475026.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POT1 | NM_015450.3 | c.1164-1G>A | splice_acceptor_variant, intron_variant | ENST00000357628.8 | NP_056265.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POT1 | ENST00000357628.8 | c.1164-1G>A | splice_acceptor_variant, intron_variant | 2 | NM_015450.3 | ENSP00000350249.3 |
Frequencies
GnomAD3 genomes AF: 0.0000198 AC: 3AN: 151808Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
151808
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0000419 AC: 61AN: 1457338Hom.: 0 Cov.: 30 AF XY: 0.0000304 AC XY: 22AN XY: 724786
GnomAD4 exome
AF:
AC:
61
AN:
1457338
Hom.:
Cov.:
30
AF XY:
AC XY:
22
AN XY:
724786
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000198 AC: 3AN: 151808Hom.: 0 Cov.: 32 AF XY: 0.0000270 AC XY: 2AN XY: 74136
GnomAD4 genome
AF:
AC:
3
AN:
151808
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74136
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Tumor predisposition syndrome 3 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 16, 2024 | This sequence change affects an acceptor splice site in intron 13 of the POT1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. Disruption of this splice site has been observed in individual(s) with clinical features of POT1 tumor predisposition syndrome (PMID: 27528712, 29625052). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 475026). Studies have shown that disruption of this splice site results in partial exon deletion and introduces a premature termination codon (PMID: 27528712; Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Nov 29, 2023 | The POT1 c.1164-1G>A intronic change results in a G to A substitution at the -1 position of intron 13 of the POT1 gene and is predicted to disrupt the acceptor splice site. This variant has been reported in individual(s) with familial melanoma (PMID: 36876055). In a large case-control study, this variant was reported in 3 of 2928 individuals with cutaneous melanoma and was not detected in 3298 controls (PMID: 36539277). This variant was also found to co-segregate with chronic lymphocytic leukemia in a family in which three individuals were affected (PMID: 27528712). Finally, it has also been observed in 1 individual with hairy cell leukemia (PMID: 34193977). This variant has a maximum subpopulation frequency of 0.0065% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). In summary, this variant meets criteria to be classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 25, 2023 | - - |
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Nov 19, 2021 | DNA sequence analysis of the POT1 gene demonstrated a sequence change in the canonical splice acceptor site in intron 13, c.1164-1G>A. This sequence change has been previously described in three family members with chronic lymphocytic leukemia (PMID: 27528712). Abnormal splicing product was detected by RT-PCR using cDNA from an individual carrying the c.1164-1G>A change (PMID: 27528712). This sequence change has been described in the gnomAD database in one individual which corresponds to a population frequency of 0.0032 % (dbSNP rs866612394). This sequence change is predicted to affect normal splicing of the POT1 gene and result in an abnormal protein. These collective evidences indicate that this sequence change is likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 05, 2024 | Canonical splice site variant demonstrated to cause aberrant splicing of exon 14 resulting in a null allele in a gene for which loss of function is a known mechanism of disease (PMID: 27528712); Observed in multiple affected individuals in a familial chronic lymphocytic leukemia kindred, as well as in other individuals with cutaneous melanoma or leukemia in published literature (PMID: 27528712, 29625052, 34193977, 36451132, 36876055); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30877237, 27528712, 29625052, 34218205, 36451132, 34193977, 34482403, 37140166, 36876055) - |
Long telomere syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | The Telomere Center at Johns Hopkins, Johns Hopkins University School of Medicine | Aug 01, 2022 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 03, 2023 | The c.1164-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide upstream from coding exon 10 of the POT1 gene. In one study, whole exome sequencing performed in familial CLL cases identified c.1164-1G>A in three siblings with CLL; their father with non-Hodgkin's lymphoma was not tested. RNA analysis on the proband with this mutation, also designated as 7:g.124481233C>T, confirmed an abnormal splicing product occurring from an alternative splice acceptor site 43 bp downstream (Speedy HE et al. Blood 2016 11;128:2319-2326). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site; however direct evidence is insufficient at this time (Ambry internal data). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: -44
DS_AL_spliceai
Position offset: -1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at